Trials / Terminated
TerminatedNCT01055067
ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors
Multicenter Phase 2 Trial of ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- Male
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, single-arm study for safety and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tivantinib (ARQ 197) | Capsule, 120 mg, BID (360 mg), approximately 112 days |
Timeline
- Start date
- 2010-02-02
- Primary completion
- 2011-11-30
- Completion
- 2011-11-30
- First posted
- 2010-01-25
- Last updated
- 2021-04-06
- Results posted
- 2020-09-09
Locations
10 sites across 3 countries: United States, France, United Kingdom
Source: ClinicalTrials.gov record NCT01055067. Inclusion in this directory is not an endorsement.